Hodgkin Lymphoma News and Research

RSS

Combination therapy shows promising results in patients with rare subtype of non-Hodgkin lymphoma

Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, showed promising results in patients with relapsed or refractory natural killer/T-cell lymphoma (R/R NKTL), a rare and aggressive cancer with limited treatment options.

15 Oct 2025

Nuclear missile workers are contracting cancer. They blame the bases.

At a memorial service in 2022, veteran Air Force Capt. Monte Watts bumped into a fellow former Minuteman III nuclear missile operator, who told him that she had non-Hodgkin lymphoma.

3 Oct 2025

The 15th AACR cancer progress report highlights scientific advances

The American Association for Cancer Research (AACR) released the 15th edition of its annual Cancer Progress Report. A cornerstone of the AACR's educational and advocacy efforts, this comprehensive report provides the latest statistics on cancer incidence, mortality, and survivorship and highlights how federal investments in basic, translational, and clinical cancer research and cancer-related population sciences have led to impressive scientific advances that are improving health and saving lives.

17 Sep 2025

Immunoglobulin replacement therapy not associated with reduced risk of serious infections in patients with CLL

In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious infections requiring hospitalization, according to a study published in Blood Advances.

31 Jul 2025

Most dairy foods linked to neutral or better health but yogurt stands out for real benefits

A major scoping review of recent systematic reviews and meta-analyses finds that most dairy products are either neutral or modestly protective for heart, cancer, metabolic, and mortality outcomes in adults. Yogurt and other fermented dairy consistently show the strongest health associations, while some risks remain for specific cancers.

28 Jul 2025

VCU Massey pioneers clinical trial of novel GGT-1 inhibitor PTX-100

VCU Massey Comprehensive Cancer Center is the first site in the United States to be activated in a global Phase 2a clinical trial evaluating PTX-100 (AKA GGTI-2418), a first-in-class small molecule inhibitor of geranylgeranyl transferase-1 (GGT-1), for the treatment of cutaneous T-cell lymphoma (CTCL), a rare and often treatment-resistant T-cell lymphoma.

26 Jul 2025

New chemotherapy regimen improves fertility outcomes in young Hodgkin's lymphoma patients

Young patients with advanced Hodgkin's lymphoma, a cancer of the lymphatic system, now have a better chance of having their own children after treatment.

10 Jul 2025

Air travel disrupts DNA repair in flight crew, raising cancer concerns

Researchers found that flight attendants show reduced DNA repair capacity and immune changes after air travel, which may help explain their higher cancer risk.

14 May 2025

Cancer rates are climbing in younger adults and researchers want to know why

A new NIH-led study finds rising rates of 14 cancer types in Americans under 50, especially breast, colorectal, kidney, uterine, and pancreatic cancers. The research urges deeper investigation into shared risk factors and earlier screening strategies.

8 May 2025

$Innovative CAR-T cell therapy achieves remarkable results in patients with refractory CD30+ lymphoma$

Innovative CAR-T cell therapy achieves remarkable results in patients with refractory CD30+ lymphoma

Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep Carreras Leukaemia Research Institute, have developed an innovative CAR-T cell therapy targeting the CD30 protein (HSP-CAR30), which has shown high efficacy in patients with refractory CD30+ lymphoma.

29 Apr 2025

Understanding the complex spectrum of Castleman disease

Castleman disease (CD) is a rare, non-clonal lymphoproliferative disorder that manifests with a wide range of histologic and clinical features.

11 Apr 2025

Novel NK cell therapy shows strong response in lymphoma patients

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

4 Apr 2025

New tool helps predict CAR T therapy outcomes for lymphoma patients

Researchers with City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, with its National Medical Center in Los Angeles ranked among the nation's top 5 cancer centers by U.S. News & World Report, and MSK have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response to chimeric antigen receptor (CAR) T cell therapy before starting the treatment, according to study results published today in Nature Medicine.

1 Apr 2025

Congenital heart defects may be linked to increased cancer risk in babies and mothers

Being born with a heart defect may be associated with an increased cancer risk for babies and their moms, according to new research published today in the American Heart Association's flagship journal Circulation.

17 Mar 2025

GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 diabetes patients, especially compared to insulin. The study also highlights GLP-1RAs’ potential as a cancer-protective treatment, independent of glucose control.

9 Mar 2025